X. Tan (1), J. Shi (2, 3), Y. Fu (1), C. Gao (3), X. Yang (1), J. Li (1), W. Wang (1), J. Hou (1), H. Li (1), J. Zhou (3)
(1) Heilongjiang Key Laboratory of Blood and Hematopoietic System Diseases, Heilongjiang Institute of Hematology and Oncology, Department of Hematology, The First Affiliated Hospital, Harbin Medical University, Harbin, China; (2) Department of Medicine, VA Boston Healthcare System, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachussetts, USA; (3) Heilongjiang Institute of Hematology and Oncology, Department of Hematology, Harbin, China
The development of thrombosis in polycythaemia vera (PV) involves multifactorial processes including pathological activation of blood cells. Release of microparticles (MPs) by activated cells in diseases is associated with thrombotic risk, but relatively few data are available in PV. The aim of the present study was to investigate the increase in MP release and exposure of phosphatidylserine (PS) on the outer membrane of MP-origin cells in patients with PV, and to analyse their procoagulant activity (PCA). PS-positive MPs and cells were detected by flow cytometry, while PCA was assessed with clotting time and purified coagulation complex assays. We found that PV patients had elevated circulating lactadherin+ MPs, which mostly originating from erythrocytes, platelets, granulocytes, and endothelial cells, as well as increased PS exposing erythrocytes/platelets as compared to secondary polycythaemia patients or healthy controls. These PS-bearing MPs and cells were highly procoagulant. Moreover, lactadherin competed factor V and VIII to PS and inhibited about 90% of the detected PCA in a dose-response manner while anti-TF antibody did no significant inhibition. Treatment with hydroxyurea is associated with a decrease in PS exposure and lactadherin+ MP release of erythrocytes/platelets. Our data demonstrate that PV patients are characterised by increased circulating procoagulant MPs and PS exposing erythrocytes/platelets, which could contribute to the hypercoagulable state in these patients.
polycythaemia vera, phosphatidylserine, microparticles, lactadherin
C. Gao (1), R. Xie (1), C. Yu (2), Q. Wang (2), F. Shi (2), C. Yao (2), R. Xie (2), J. Zhou (1), G. E. Gilbert (3), J. Shi (1, 3)
Thromb Haemost 2012 107 4: 681-689
Y. Fu (1), J. Zhou (1), H. Li (1), F. Cao (1), Y. Su (1), S. Fan (1), Y. Li (1), S. Wang (1), L. Li (1), G. E. Gilbert (2), J. Shi (1, 2)
Thromb Haemost 2010 104 6: 1235-1241
M. Skeppholm (1), F. Mobarrez (1), K. Malmqvist (1), H. Wallén (1)
Thromb Haemost 2012 107 6: 1122-1129
Patients receiving oral anticoagulants should be carefully managed to minimize the risk of bleeding...
Acquired haemophilia A (AHA) is a rare but often severe bleeding disorder caused by ...
Section III " Vitamin K antagonists in heart disease: Current status and perspectives" of...